Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|18|3212-3220

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.18, 2015-09, pp. : 3212-3220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 491-496

Karger

Access to resources Recommend Favorite

Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2570-2577

John Wiley & Sons Inc

Access to resources Recommend Favorite

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-04 ,pp. : 98-105

Karger

Access to resources Recommend Favorite

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2289-2298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite